Experimental pill aims to tame deadly inflammation in severe COVID

NCT ID NCT04469621

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tested an oral drug called SAR443122 in 68 hospitalized adults with severe COVID-19. The goal was to see if the drug could safely reduce harmful inflammation, measured by a blood marker called CRP. Participants were randomly assigned to receive the drug or a placebo, and researchers tracked their oxygen needs and recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAR443122 (a RIPK1 inhibitor drug taken orally)
What this could lead to: If successful, this could point toward a treatment that calms the dangerous overactive immune response in severe COVID-19, potentially reducing the need for oxygen or ventilator support.
What could go wrong: This is an early phase 1b trial with only 68 participants, so results may not apply broadly. The drug may not improve outcomes or could have side effects not yet seen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONA VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONA VIRUS INFECTION

Contacts and locations

Locations

Investigational Site Number 0320001

Caba, 1430, Argentina
Investigational Site Number 0760001

São José do Rio Preto, 15090-000, Brazil
Investigational Site Number 0760002

São Paulo, 04321-120, Brazil
Investigational Site Number 0760003

Porto Alegre, 90035 003, Brazil
Investigational Site Number 1520001

Santiago, 750-0691, Chile
Investigational Site Number 1520002

Talca, 3460001, Chile
Investigational Site Number 1520003

Santiago, 8900085, Chile
Investigational Site Number 4840001

Monterrey, 64460, Mexico
Investigational Site Number 6430001

Moscow, 111539, Russia
Investigational Site Number 6430002

Moscow, 123182, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.